1. Prognostic Value of
- Author
-
Marc, Hilmi, Cindy, Neuzillet, Jérémie H, Lefèvre, Magali, Svrcek, Sophie, Vacher, Leonor, Benhaim, Peggy, Dartigues, Emmanuelle, Samalin, Julien, Lazartigues, Jean-François, Emile, Eugénie, Rigault, Nathalie, Rioux-Leclercq, Christelle, de La Fouchardière, David, Tougeron, Wulfran, Cacheux, Pascale, Mariani, Laura, Courtois, Matthieu, Delaye, Virginie, Dangles-Marie, Astrid, Lièvre, and Ivan, Bieche
- Subjects
Adult ,Aged, 80 and over ,Male ,Lung Neoplasms ,Time Factors ,Antineoplastic Agents ,Exons ,Middle Aged ,ErbB Receptors ,Mutagenesis, Insertional ,Young Adult ,Phenotype ,Treatment Outcome ,Drug Resistance, Neoplasm ,Carcinoma, Non-Small-Cell Lung ,Disease Progression ,Humans ,Female ,Genetic Predisposition to Disease ,Registries ,Protein Kinase Inhibitors ,Aged ,Czech Republic ,Retrospective Studies - Abstract
Per literature, patients with epidermal growth factor receptor (EGFR) exon-20 insertions respond poorly to tyrosine kinase inhibitors (TKIs). This study analyzed real-world data to examine the prognostic and predictive value of these mutations.We conducted a retrospective cohort study using Czech TULUNG Registry data, with data on multiple mutation types, collected in 2011-2020.We analyzed 554 (95.85%) patients with EGFR exon-19 deletions or exon-21 L858R substitutions and 24 (4.15%) patients with exon-20 insertions who received first-line high-value therapies. We summarized clinical characteristics and outcomes in all patients and by cohort. The risk of progression was statistically significantly higher (86%) in the exon-20 insertion cohort compared to the cohort with other mutations. Although not statistically significant, the risk of death was 44% higher in patients with exon-20 insertions.Advanced NSCLC patients with rare EGFR exon-20 insertions have a high risk of progression.
- Published
- 2021